Intervention

TLR8 Agonist VTX-2337

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 1 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials1

Recruiting0

Common conditions17

Lead sponsors shown1

Clinical trials

1 shown

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635 · 2016-02-05

TERMINATED

Common conditions

Colorectal Adenocarcinoma1 Metastatic Pancreatic Adenocarcinoma1 Recurrent Breast Carcinoma1 Recurrent Colorectal Carcinoma1 Recurrent Melanoma of the Skin1 Recurrent Non-Small Cell Lung Carcinoma1 Recurrent Pancreatic Carcinoma1 Recurrent Renal Cell Carcinoma1 Solid Neoplasm1 Stage IV Breast Cancer1 Stage IV Non-Small Cell Lung Cancer1 Stage IV Renal Cell Cancer1 Stage IV Skin Melanoma1 Stage IVA Colorectal Cancer1 Stage IVA Pancreatic Cancer1 Stage IVB Colorectal Cancer1 Stage IVB Pancreatic Cancer1

Leading sponsors

Mayo Clinic 1

Trial status mix

TERMINATED1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.